Шкірні побічні ефекти онкологічного лікування. Частина I. Хіміотерапія
DOI:
https://doi.org/10.30978/UJDVK2018-3-62Ключові слова:
хіміотерапія, побічні ефекти, висип, синдром шкіри долонь і стоп, стоматит, алопеція, профілактика, лікуванняАнотація
Існує два терапевтичних шляхи для пацієнтів онкологічного профілю: променева терапія і хіміотерапія. Останню поділяють на традиційну і цільову.
Обидві категорії хіміотерапевтичного лікування дають побічні ефекти, хоча вони частіше бувають у разі традиційної хіміотерапії, ніж цільової. Ці побічні ефекти часто впливають на шкіру, волосся і нігті. У цьому огляді розглянуто всі категорії хіміотерапевтичних препаратів та описано побічні впливи, пов’язані з кожним лікарським засобом. Найтяжчими є реакції гіперчутливості, які можуть загрожувати життю пацієнта. Крім того, найпоширенішими нашкірними реакціями є макулопустулярний або папулопустульозний висип, синдром шкіри долонь і стоп, набряк, еритема, гіперпігментаційні розлади або реакції фоточутливості. Стоматит також часто уражує слизову оболонку порожнини рота. Що стосується волосся, то часто бувають анагенне випадіння волосся і алопеція, крім того, багато з цих процедур також впливають на нігті. У пропонованому огляді описано ці побічні ефекти, їхні симптоми і діагностику, рекомендації щодо профілактики та лікування.
Посилання
Reyes-Habito CM, Roh EK. Cutaneous reactions to chemotherapeutic drugs and targeted therapies for cancer: part I. Conventional chemotherapeutic drugs. J Am Acad Dermatol. 2014;71(2):203.e1-203.e12.
Susser WS, Whitaker-Worth DL, Grant-Kels JM. Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol. 1999 Mar;40(3):367-98.
Rosman IS, Lloyd BM, Hayashi RJ, Bayliss SJ. Cutaneous effects of thiotepa in pediatric patients receiving high-dose chemotherapy with autologous stem cell transplantation. J Am Acad Dermatol. 2008;58:575-8.
Makrilia N, Syrigou E, Kaklamanos I, Manolopoulos L, Saif MW. Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs 2010;2010. pii: 207084. Epub 2010 Sept 20.
de Jonge ME, Mathôt RA, Dalesio O, Huitema AD, Rodenhuis S, Beijnen JH. Relationship between irreversible alopecia and exposure to cyclophosphamide, thiotepa and carboplatin (CTC) in high-dose chemotherapy. Bone Marrow Transplant. 2002;30:593-7.
Yildiz O, Ozguroglu M, Yanmaz MT, Turna H, Kursunoglu SG, Antonov M, et al. Paraneoplastic pemphigus associated with fludarabine use. Med Oncol 2007;24:115-8.
Meunier P, Castaigne S, Bastie JN, Chosidow O, Aractingi S. Cutaneous reactions after treatment with 2-chlorodeoxyadenosine. Acta Derm Venereol. 1996;76:385-6.
Ganzel C, Gatt ME, Maly A, Ben-Yehuda D, Goldschmidt N. High incidence of skin rash in patients with hairy cell leukemia treated with cladribine. Leuk Lymphoma. 2012;53:1169-73.
Chu CY, Yang CH, Chiu HC. Gemcitabine-induced acute lipodermatosclerosis-like reaction. Acta Derm Venereol. 2001;81:426-8.
del Pozo J, Martınez W, Yebra-Pimentel MT, Almagro M, Peña-Penabad C, Fonseca E. Linear immunoglobulin A bullous dermatosis induced by gemcitabine. Ann Pharmacother. 2001;35:891-3.
Sommers KR, Kong KM, Bui DT, Fruehauf JP, Holcombe RF. Stevens-Johnson syndrome/toxic epidermal necrolysis in a patient receiving concurrent radiation and gemcitabine. Anticancer Drugs. 2003;14:659-62.
Rusthoven JJ, Eisenhauer E, Butts C, Gregg R, Dancey J, Fisher B, et al. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a phase II study. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1999;17:1194.
Eguia B, Ruppert AM, Fillon J, Lavole A, Gounant V, Epaud C, et al. Skin toxicities compromise prolonged pemetrexed treatment. J Thorac Oncol. 2011;6:2083-9.
Rosen A, Amitay-Laish I, Lacouture M. Management algorithms for dermatologic adverse events. In: Lacouture ME, editor. Dermatologic principles and practice in oncology: conditions of the skin, hair and nails in cancer patients. 1st ed. Philadelphia (PA): Wiley-Blackwell; 2014. pp. 367-83.
Fabian CJ, Molina R, Slavik M, Dahlberg S, Giri S, Stephens R. Pyridoxine therapy for palmar-plantar eythrodysesthesia associated with continuous 5 fluorouracil infusion. Invest New Drugs. 1990;8:57-63.
Llistosella E, Codina A, Alvarez R, Pujol RM, de Moragas JM. Tegafur-induced acral hyperpigmentation. Cutis. 1991;48:205-7.
Hureaux J, Le Guen Y, Tuchais C, Savary L, Urban T. Radiation recall dermatitis with pemetrexed. Lung Cancer. 2005;50:255-8.
von Gruenigen V, Frasure H, Fusco N, DeBernardo R, Eldermire E, Eaton S, et al. A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients. Cancer. 2010;116:4735-43.
von Moos R, Thuerlimann BJ, Aapro M, Rayson D, Harrold K, Sehouli J, et al. Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. Eur J Cancer. 2008;44:781-90.
Salzberg M, Thurlimann B, Hasler U, Delmore G, von Rohr A, Thurlimann A, et al. Pegylated liposomal doxorubicin(caelyx) in metastatic breast cancer: a community-based observation study. Oncology. 2007;72:147-51.
Lotem M, Hubert A, Lyass O, Goldenhersh MA, Ingber A, Peretz T, et al. Skin toxic effects polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol. 2000; 136:1475-80.
Wolf R, Wolf D. Bleomycin-induced flagellate dermatitis. Int J Dermatol. 2011;50:546-7.
Yamamoto T. Bleomycin and the skin. Br J Dermatol. 2006; 155:869-75.
Lau CP, Hui P, Chan TC. Docetaxel-induced nail toxicity: a case of severe onycholysis and topic review. Chin Med J (Engl). 2011;124:2559-60.
Reyes-Habito CM, Roh EK. Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: Part II. Targeted therapy. J Am Acad Dermatol. 2014 Aug;71(2):217.e1-217.e11.
Amitay-Laish I, Stemmer SM, Lacouture ME. Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib. Dermatol Ther. 2011;24:386-95.
Valeyrie L, Bastuji-Garin S, Revuz J, et al. Adverse cutaneous reactions to imatinib (STI-571) in Philadelphia chromosome positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol. 2003;48: 201-206.
Arora B, Kumar L, Sharma A, Wadhwa J, Kochupillai JWV. Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate. Ann Oncol. 2004;15: 358– 359.
Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110: 3540-3546.
Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006: 354: 2531-2541.
Heidary N, Naik H, Burgin S. Chemotherapeutic agents and the skin: an update. J Am Acad Dermatol. 2008;58:545-70.
Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan A, Epstein JB, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011;19:1079-95.
Wu KL, Heule F, Lam K, Sonneveld P. Pleomorphic presentation of cutaneous lesions associated with the proteasome inhibitor bortezomib in patients with multiple myeloma. J Am Acad Dermatol. 2006;55:897-900.
Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, Choi JH, et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol. 2009;161:1045-51.
Lipworth AD, Robert C, Zhu AX. Hand-foot syndrome (handfoot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology. 2009;77:257-71.
Dubauskas Z, Kunishige J, Prieto VG, Jonasch E, Hwu P, Tannir NM. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer. 2009;7:20-3.
Kähler KC, Hauschild A. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma. J Dtsch Dermatol Ges. 2011;9:277-86.
Manousaridis I, Mavridou S, Goerdt S, Leverkus M, Utikal J. Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management. J Eur Acad Dermatol Venereol. 2013;27:11-8.
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-16.
Anforth RM, Blumetti TCMP, Kefford RF, Sharma R, Scolyer RA, Kossard S, et al. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br J Dermatol. 2012;167:1153-60.
Trefzer U, Minor D, Ribas A, Lebbe C, Siegfried A, Arya N, et al. BREAK-2: a phase IIA trial of the selective BRAF kinase inhibitor GSK2118436 in patients with BRAF mutation-positive (V600E/K) metastatic melanoma. Pigment Cell Res. 2011;24:990-1075.
Granai C, Frederickson H, Gajewski W, Goodman A, Goldstein A, Baden H. The use of minoxidil to attempt to prevent alopecia during chemotherapy for gynaecologic malignancies. Eur J Gynaecol Oncol. 1991;12:129-32.
Madeya M. Oral complications from cancer therapy: part 2-nursing implications for assessment and treatment. Oncol Nurs Forum. 1996;23:808-19.
Fischer D, Knobf M, Durivage H. The cancer chemotherapy handbook. St Louis: Mosby; 1997 p. 514-26.
Vukelja S, Baker W, Burris H, Keeling J, Von Hoff D. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with taxotere. J Natl Cancer Inst. 1993;85:1432-3.
Schweitzer V, Juillard G, Bajada C, Parker R. Radiation recall dermatitis and pneumonitis in a patient treated with paclitaxel. Cancer. 1995;76:1069-72.
Potter T, Hashimoto K. Cutaneous photosensitivity to medications. Compr Ther. 1994;20:414-7.
Hamm RL. Drug-Hypersensitivity Syndrome: Diagnosis and Treatment. J Am Coll Clin Wound Spec. 2011;3(4):77-81.
Chowta NK, Chowta MN, Ramapuram J, Kumar P, Fazil A: Carbamzepine-induced toxic epidermal necrolysis. Indian J Crit Care Med. 2011;15(2):123-125.
Bidoli P, Cortinovis DL, Colombo I, Crippa A, Cicchiello F, Villa F, et al. Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer. J Thorac Oncol. 2010;5:1662-3.
